FDA.reportPublic FDA data

METACRESOL

Substance profile for UNII GGO4Y809LO, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for METACRESOL
Structure render from PubChem CID 342

Substance Identity#

UNII
GGO4Y809LO
Preferred term
METACRESOL
Registry number
108-39-4
EC number
203-577-9
Ingredient type
INGREDIENT SUBSTANCE
Molecular formula
C7H8O
Chemical structure for METACRESOL
Structure render from PubChem CID 342

Chemical And Database Identifiers#

InChIKey
RLSSMJSEOOYNOY-UHFFFAOYSA-N
SMILES
CC1=CC(O)=CC=C1
RxCUI
1367170
PubChem
342
NCIt
C80603
INN ID
0

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem Compound342pubchem.ncbi.nlm.nih.gov/compound/342
PubChem InChIKey SearchRLSSMJSEOOYNOY-UHFFFAOYSA-Npubchem.ncbi.nlm.nih.gov/#query=RLSSMJSEOOYNOY-UHFFFAOYSA-N
RxNorm1367170mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1367170
NCI ThesaurusC80603ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C80603
FDA Substance Registration SystemGGO4Y809LOprecision.fda.gov/uniisearch/srs/unii/GGO4Y809LO
European Community number203-577-9commonchemistry.cas.org/results?q=203-577-9

DailyMed Socrata Ingredients#

DailyMed label, SPL version table
DailyMed labelSPL version
These highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 2000 ®2
These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. LANTUS (insulin glargine [rDNA origin] injection) solution for subcutaneous injection Initial U.S. Approval: 20002
Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin) ®2
Novolin N NPH, Human Insulin Isophane Suspension (recombinant DNA origin) 100 units/mL2
These highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog ® (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 20001
These highlights do not include all the information needed to use Novolin R safely and effectively. See full prescribing information for Novolin R. Initial U.S. Approval: 1991 Novolin R (Regular, Human Insulin [rDNA origin] USP) solution for subcutaneous or intravenous use ®2
These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG. Humalog (insulin lispro injection, USP [rDNA origin]) for injection Initial U.S. Approval: 19962
These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG. Humalog (insulin lispro injection, USP [rDNA origin]) for injection Initial U.S. Approval: 19963
These highlights do not include all the information needed to use BYETTA safely and effectively. See full prescribing information for BYETTA. BYETTA ® (exenatide) Injection Initial U.S. Approval: 20053
These highlights do not include all the information needed to use LEVEMIR ® safely and effectively. See full prescribing information for LEVEMIR. LEVEMIR ® (insulin detemir [rDNA origin] injection) solution for subcutaneous injection Initial U.S. Approval: 20052
Novolin ® 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)2
These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. LANTUS (insulin glargine [rDNA origin] injection) solution for subcutaneous injection Initial U.S. Approval: 20001
Levemir ® (insulin detemir [rDNA origin] injection)1
HUMULIN ® R REGULAR INSULIN HUMAN INJECTION, USP (rDNA ORIGIN)100 UNITS PER ML (U-100)2
These highlights do not include all the information needed to use NovoLog Mix 70/30 safely and effectively. See full prescribing information for NovoLog Mix 70/30. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Suspension for subcutaneous injection Initial U.S. Approval: 20012
81f28314-31c8-4114-a4b3-336eb20945581
44863566-b55c-422d-adbd-5454a70b68a91
These highlights do not include all the information needed to use LANTUS safely and effectively. See full prescribing information for LANTUS. LANTUS (insulin glargine [rDNA origin] injection) solution for subcutaneous injection Initial U.S. Approval: 20002
HUMALOG (INSULIN LISPRO) INJECTION, SOLUTION HUMALOG KWIKPEN (INSULIN LISPRO) INJECTION, SOLUTION [ELI LILLY AND COMPANY]49
HUMALOG MIX50/50 (INSULIN LISPRO) INJECTION, SUSPENSION HUMALOG MIX50/50 KWIKPEN (INSULIN LISPRO) INJECTION, SUSPENSION [ELI LILLY AND COMPANY]32
HUMALOG MIX75/25 (INSULIN LISPRO) INJECTION, SUSPENSION HUMALOG MIX75/25 KWIKPEN (INSULIN LISPRO) INJECTION, SUSPENSION [ELI LILLY AND COMPANY ]31
FORTEO (TERIPARATIDE) INJECTION, SOLUTION [ELI LILLY AND COMPANY]23
HUMULIN R (INSULIN HUMAN) INJECTION, SOLUTION [ELI LILLY AND COMPANY ]22
LANTUS (INSULIN GLARGINE) INJECTION, SOLUTION LANTUS SOLOSTAR (INSULIN GLARGINE) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]22
BYETTA (EXENATIDE) INJECTION [AMYLIN PHARMACEUTICALS, LLC]20
NOVOLOG (INSULIN ASPART) INJECTION, SOLUTION [NOVO NORDISK]19
NOVOLOG MIX 70/30 (INSULIN ASPART) INJECTION, SUSPENSION [NOVO NORDISK]16
APIDRA (INSULIN GLULISINE) INJECTION, SOLUTION APIDRA SOLOSTAR (INSULIN GLULISINE) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]15
HUMULIN R U-500 (INSULIN HUMAN) INJECTION, SOLUTION [ELI LILLY AND COMPANY ]15
LEVEMIR (INSULIN DETEMIR) INJECTION, SOLUTION [NOVO NORDISK]15
REMODULIN (TREPROSTINIL) INJECTION, SOLUTION [UNITED THERAPEUTICS CORPORATION]14
DEMEROL (MEPERIDINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.]12
NOVOLIN R (HUMAN INSULIN) INJECTION, SOLUTION [NOVO NORDISK]12
SYMLINPEN (PRAMLINTIDE ACETATE) INJECTION [AMYLIN PHARMACEUTICALS, LLC]11
NOVOLIN N (HUMAN INSULIN) INJECTION, SUSPENSION [NOVO NORDISK]10
NOVOLIN 70/30 (HUMAN INSULIN) INJECTION, SUSPENSION [NOVO NORDISK]9
SAIZEN (SOMATROPIN) KIT SAIZEN CLICKEASY (SOMATROPIN) KIT [EMD SERONO, INC.]7
TOUJEO (INSULIN GLARGINE) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]7
GONAL-F RFF PEN (FOLLTROPIN ALFA) INJECTION, SOLUTION [EMD SERONO, INC.]5
GONAL-F RFF REDI-JECT (FOLLITROPIN) INJECTION, SOLUTION [EMD SERONO, INC.]3
INTRON A (INTERFERON ALFA-2B) KIT INTRON A (INTERFERON ALFA-2B) INJECTION, SOLUTION [MERCK SHARP & DOHME CORP.]3
SYMLINPEN (PRAMLINTIDE ACETATE) INJECTION [ASTRAZENECA PHARMACEUTICALS LP]3
BYETTA (EXENATIDE) INJECTION [ASTRAZENECA PHARMACEUTICALS LP]2
CERENIA (MAROPITANT CITRATE) INJECTION [ZOETIS INC.]2
NATPARA (PARATHYROID HORMONE) (PARATHYROID HORMONE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [NPS PHARMACEUTICALS, INC.]2
HUMULIN 70/30 70/30 (INSULIN HUMAN) INJECTION, SUSPENSION [REMEDYREPACK INC. ]1
HUMULIN 70/30 70/30 (INSULIN HUMAN) INJECTION, SUSPENSION [REMEDYREPACK INC. ]1
LANTUS (INSULIN GLARGINE) INJECTION, SOLUTION [REMEDYREPACK INC. ]1
LANTUS (INSULIN GLARGINE) INJECTION, SOLUTION [REMEDYREPACK INC. ]1
NOVOLIN 70/30 (HUMAN INSULIN) INJECTION, SUSPENSION [A-S MEDICATION SOLUTIONS LLC]1
NOVOLIN70/30 70/30 (HUMAN INSULIN) INJECTION, SUSPENSION [REMEDYREPACK INC. ]1
NOVOLIN70/30 70/30 (HUMAN INSULIN) INJECTION, SUSPENSION [REMEDYREPACK INC. ]1
REGRANEX (BECAPLERMIN) GEL [HEALTHPOINT, LTD]1
REGRANEX (BECAPLERMIN) GEL [SMITH & NEPHEW, INC.]1
TRESIBA (INSULIN DEGLUDEC INJECTION) INJECTION, SOLUTION [NOVO NORDISK]1
ZOMACTON (SOMATROPIN) KIT [FERRING PHARMACEUTICALS INC.]1

Inactive Ingredient Database#

Browse recovered IID releases and source provenance.

Current IID rows for UNII GGO4Y809LO page 1 of 1 · 7 matching rows.

Ingredient, UNII, CAS table
IngredientUNIICASDosage formRoutePotencyMaximum daily exposure
METACRESOLGGO4Y809LO108394INJECTIONINTRADERMAL0.16 %w/v
METACRESOLGGO4Y809LO108394INJECTIONINTRAMUSCULAR0.1 %w/v
METACRESOLGGO4Y809LO108394INJECTIONINTRAVENOUS0.3 %w/v
METACRESOLGGO4Y809LO108394INJECTIONSUBCUTANEOUS0.3 %w/v
METACRESOLGGO4Y809LO108394INJECTION, SOLUTIONSUBCUTANEOUS0.3 %w/v
METACRESOLGGO4Y809LO108394INJECTION, SUSPENSIONSUBCUTANEOUS0.16 %w/v
METACRESOLGGO4Y809LO108394SOLUTIONSUBCUTANEOUS0.3 %w/v